Cahill Represents Financing Sources in Integra LifeSciences' $2.1 Billion Debt Financing

Date: 10/19/26

Cahill represented the initial purchasers and the lead arrangers in connection with a $2.1 billion debt financing consisting of a $450 million inaugural high-yield issuance of 9.5% senior secured notes due 2033 offered pursuant to Rule 144A and Regulation S, a $600 million senior secured revolving credit facility with a five-year maturity, a $600 million senior secured term loan A facility with a five-year maturity, and an inaugural $450 million senior secured term loan B facility with a seven-year maturity.

Proceeds from the notes offering were used along with proceeds from the credit facilities to refinance Integra LifeSciences' existing credit facilities in full.

Integra LifeSciences is a global leader in medical technology offering innovative solutions, including leading regenerative technologies in specialty surgical solutions, orthopedics, and tissue technologies.

Attorneys

- Stuart Downing
- Katharine Donaldson
- Myah L. Blythe
- Abigail A. Kucharczyk
- Dia D. Su
- Reilly Golden
- Bruna M. Amaral
- Howard L. Silverman

Practice

- Banking & Finance